Definium (DFTX) CEO Robert Barrow Receives Award of 750,000 Shares

What Happened
Robert Barrow, Chief Executive Officer of Definium Therapeutics (DFTX), was reported as acquiring 750,000 common shares via an award/grant on 2026-09-14. The report shows $0.00 paid per share (award), so no cash was exchanged in this transaction. This is an award/retention-style grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-09-14 (filed 2026-09-14, Accession: 0001193125-26-389887)
• Transaction type/code: Award/Grant (A) — 750,000 shares acquired at $0.00 per share
• Shares owned after transaction: Not specified in the filing excerpt provided
• Footnote summary: These common shares represent the third tranche of performance share units (PSUs) originally granted effective March 12, 2025. They remain subject to vesting based on continued employment through March 12, 2028 and are contingent on the achievement of certain clinical and regulatory milestones per the PSU award agreement.
• Filing status: Document filed on the same date shown (no late-filing flag provided in the excerpt)

Context
This award is performance- and service-based: although recorded as an acquisition, the shares are contingent and subject to future vesting and milestone conditions, so they do not necessarily represent immediately transferable or saleable shares. Such awards are common as long-term incentive and retention tools and are not the same signal as an outright open-market purchase by an insider.